ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Caixin

Chinese mRNA vaccine developer raises a record $200m

Fresh funds to finance clinical trials and production of vaccine candidate

Venture capital is continuing to pour into the novel technology to fight COVID-19 and future viral threats.   © Reuters

Vaccine startup Stemirna Therapeutics has raised $200 million -- a record for Chinese vaccine developers specializing in messenger RNA (mRNA) technology -- showing that venture capital continues to bet on the technology to combat the COVID-19 pandemic and future viral threats.

The fundraising, the ninth investment round for Chinese mRNA vaccine enterprises since 2020, was led by investors including China Merchants Group's health sector investment arm, Sequoia Capital China and pharmaceutical company WuXi AppTec, Stemirna said.

The Shanghai-based company's vaccine candidate will soon start Phase 2 trials and is expected to show effectiveness against variants found in South Africa, Brazil and India, founder and CEO Li Hangwen said. The funds will finance clinical trials and production of the vaccine candidate, the company said.

Currently two mRNA vaccines -- one developed by Pfizer and BioNTech and another by Moderna -- are in use globally. The mRNA technology delivers a bit of genetic code to cells, teaching the cells how to make a protein that triggers an immune response to the virus.

Those vaccines outperformed others in clinical trials. The Pfizer vaccine showed efficacy of 95% at preventing symptomatic infection after two doses, while Moderna's was 94.1% effective, compared with 79.34% for Sinopharm's inactivated virus vaccine.

The mRNA vaccines are by far the most widely administered COVID-19 shots in the world and have shown promising results, both in clinical trials and the real world. Compared with other vaccines, mRNA inoculations can be rapidly adjusted to respond to viral mutations and are capable of activating stronger cellular immunity, Stemirna's CEO said.

Stemirna's record fundraising followed a 600 million yuan Series B round by Suzhou Abogen Biosciences in April from investors including PICC Capital Equity Investment, SDIC Venture Capital and Alibaba founder Jack Ma's Yunfeng Capital.

An mRNA COVID-19 vaccine jointly developed by Abogen and the Institute of Military Medicine under the Academy of Military Sciences started a Phase 3 clinical trial in May.

The mRNA vaccines have high production barriers and only a few companies have mastered the technology, said Abogen founder Ying Bo.

--

Read also the original story.

Caixinglobal.com is the English-language online news portal of Chinese financial and business news media group Caixin. Nikkei recently agreed with the company to exchange articles in English.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more